OXFORD BIOMEDICA BEGINS TROVAX TRIAL

A A

Oxford BioMedica has treated the first patient in a second Phase II trial with TroVax in combination with interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC). There are now five Phase II trials ongoing with TroVax in RCC and colorectal cancer.

This open-label trial is expected to recruit up to 25 patients, and is designed to evaluate the safety and immunogenicity of TroVax in conjunction with low dose IL-2, which is commonly used in the treatment of RCC. Initial data from the trial are expected in the first half of 2006.